Fast-growing semiconductor and next-generation biotech stocks can create lucrative new markets in healthcare and computing and beat the benchmark over the long term, says Martin Currie’s equities investment boss, Zehrid Osmani.
The fund manager said Martin Currie’s global fund also owns $US32.4 billion Nasdaq-listed genetic sequencing biotech Illumina. Grail also uses some of Illumina’s gene sequencing technology to deliver the result for its fast-selling blood tests.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FinancialReview - 🏆 2. / 90 Read more »